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Abstract Since the introduction of the bivalent human papil-
loma virus (HPV) vaccine in the Netherlands, migraine has
been reported as a notable event in the passive safety surveil-
lance system. Research on the association between HPV vac-
cination and migraine is needed. Therefore, potential migraine
cases in 2008–2010 were selected from a group of general
practitioners and linked to the vaccination registry. Data were
analysed in three ways: (i) incidences of migraine postvaccina-
tion (2009/2010) were compared to pre-vaccination incidences
(2008); (ii) in a cohort, incidence rates of migraine in vaccinated
and unvaccinated girls were compared and (iii) in a self-
controlled case series analysis, the relative incidence of mi-
graine in potentially high-risk periods was compared to non-
high-risk periods. Incidence rates of migraine for 12- to 16-
year-old girls and boys postvaccination were slightly higher
than pre-vaccination incidence rates. Incidence rate ratios
(IRRs) for vaccinated compared to unvaccinated girls were
not statistically significantly higher. Furthermore, the RR for
migraine in the high-risk period of 6 weeks following each dose
versus non-high-risk period was 4.3 (95% confidence interval
(CI) 0.69–26.6) for certain migraine.
Conclusion: Using different methods, no statistically sig-
nificant association between HPV vaccination and incident
migraine was found. However, the number of cases was low;
to definitively exclude the risk, an increased sample size is
needed.
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Abbreviations
CI Confidence interval
GBS Guillain-Barré syndrome
GP General practitioner
HPV Human papilloma virus
ICPC International Classification of Primary Care
IPCI Integrated Primary Care Information
IRR Incidence rate ratio
NIP National Immunisation Programme
SCCS Self-controlled case series
Introduction
Vaccination against human papilloma virus (HPV) with the
bivalent HPV-16/18 vaccine (Cervarix®) was introduced in
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the Dutch National Immunisation Programme (NIP) in 2010
and has been provided annually to 12-year-old girls born in
1997 or later. Prior to the introduction of the vaccination into
the NIP, a catch-up campaign was organised in 2009 for 13- to
16-year-old girls (i.e. born in 1993–1996) [8]. This campaign
was extended in 2010 for girls who were not completely
vaccinated. Vaccination coverage in 2009 and 2010 ranged
per birth cohort between 49 and 56 %.
In the Netherlands, a national enhanced passive safety
surveillance system has been in place since 1962. Reporting
criteria are broad, and adverse events following immunisation
can be reported by telephone or digitally. A new and notable
event in the enhanced passive safety surveillance system for
adverse events since the introduction of HPV vaccination was
the number of reports of migraine. In 2009 and 2010, 52
reports of headache have been received following almost
800,000 doses of HPV vaccine [30]. Eight cases were diag-
nosed as migraines, of which three of the patients were born in
1994, one in 1995, two in 1996 and two in 1997. Headaches
are known to be frequently reported following administration
of the HPV vaccine [9, 11, 19]. However, migraine headaches
can be severe, and attacks can occur regularly. Because back-
ground incidence rates for migraines are lacking, it is un-
known whether the number of cases is more frequent in
comparison to what can be expected for girls in this age range.
For seven out of the eight reports of migraine in the passive
safety surveillance system, an expert panel assessed that it was
improbable that the cause was vaccination [25, 26]. This
assessment was based on the following points of consider-
ation: diagnosis with severity and duration, time interval,
biological plausibility, specificity of the symptoms, indica-
tions for other causes, proof for vaccine causation and under-
lying illness or concomitant health problems. In addition, no
plausible pathophysiological mechanism is known to explain
how migraine may be caused by HPV vaccination. Vaccina-
tion may act as a trigger for migraine, i.e. provocative factor
for an attack. Although, according to many experts, the value
of triggers is overestimated [14].
Migraine is characterised by recurrent moderate to severe
attacks of usually unilateral, pulsating headaches with nausea
and/or vomiting. The headache worsens with physical activity,
and there is often increased sensitivity to light (photophobia) and
sounds (phonophobia). Headaches last from 4 to 72 h in patients
15 years and older [13] and from 1 to 72 h in children younger
than 15 years old [3, 15]. Migraine may be preceded by an aura,
a transient focal neurological phenomenon that usually is visual
[13]. The cause of migraine is unknown, and the value of
triggers that cause an attack is difficult to prove. Migraines can
occur in any patient from approximately 3 years of age. In
childhood, migraine is more common in boys than in girls, but
in puberty, the incidence of migraine in girls rises above that in
boys [2]. The duration of migraine attacks in children is different
than attacks in adults; the duration can be shorter in children and
often lasts for only 1 h [3]. Therefore, doctors do not always
identify migraines in children [12] and often misdiagnose mi-
graines as tension headaches. In puberty, the character of the
attacks changes, leading to a diagnosis of migraine.
The estimated lifetime prevalence of migraine for 20- to
65-year-old Dutch women is 33 % [18]. The prevalence of
migraine in children 6–16 years old, with a case definition of
headache attacks lasting 2–8 h associated with symptoms such
as photophobia or nausea or preceded by an aura, is estimated
at 8 % [28]. The incidence in general practices is approxi-
mately one new migraine patient per month [17].
In a previous study in the Dutch general population [32],
we analysed the long-term occurrence of headache incidence
in HPV-vaccinated and unvaccinated girls more than 1 year
after the HPV vaccination campaign. At 14 years of age, no
higher risk of having headache attacks (odds ratio (OR) 0.67,
95 % confidence interval (CI) 0.37–1.21), self-reported mi-
graine or severe headaches (OR 0.96, 95 % CI 0.40–2.34) and
migraine symptoms (i.e. headache attacks mostly during 1 h
or more and at least two of the following characteristics: a
pulsating pain, unilateral, severe enough to avoid going to
school or other activities; OR 0.39, 95%CI 0.15–1.00), with a
first attack on or after 12 years of age, was found in the
12 months before the study questionnaire administration for
HPV-vaccinated girls (n=751) compared with unvaccinated
girls (n=368) [27]. Moreover, in this study, we aimed to
investigate whether there is an association between HPV
vaccination and incident migraine on a short term following
administration of the bivalent HPV vaccine by using three
different study designs. Even in a small number, reports of
adverse events can easily lead to negative attention towards
HPV vaccination. Therefore, research on the association be-
tween HPV vaccination and migraine is necessary to maintain
trust in the NIP.
Materials and methods
Design
First, we applied a population-based study to estimate the
incidence of migraine in the population pre- and post-
introduction of the HPV vaccination programme. Further-
more, we conducted a cohort study and a self-controlled case
series (SCCS) analysis in girls from 20 general practitioners
(GPs) who agreed to provide data for linkage with the vacci-
nation registry to assess the association between HPV
vaccination and migraine.
Setting
The department of Medical Informatics of the Erasmus Uni-
versity Rotterdam developed an electronic database of
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medical records from Dutch GPs, the Integrated Primary Care
Information (IPCI) database. The database is designed for
post-marketing surveillance and pharmaco-epidemiological
research [31]. IPCI is a longitudinal observational database,
which contains digital medical patient records fromGPs in the
Netherlands. At present, the database contains demographic
information, medical notes, prescriptions and indications for
therapy, referrals, hospitalisations and laboratory results for
about 1,500,000 patients from 600 GPs, which is almost 9 %
of the total Dutch population. For coding, the Dutch standard
for GPs for the classification of symptoms and diseases, the
International Classification of Primary Care (ICPC) is used in
addition to free text.
Study population
Data from all individuals between 1 January 2007 and 31
December 2010 in the IPCI database were used for case
selection. Date of entry in the study was defined as 1 January
2008 or the date at which 1 year of valid data history in the
database was accumulated if this was later. The date of the end
of the study was 31 December 2010 or the end of registration
of the patient, death or last IPCI data delivery if this was
earlier. This entire study population was used to compare
age- and gender-specific incidences of migraine before and
after the introduction of the HPV vaccination programme.
Additionally, a small cohort from this study population was
used to compare incidences of migraine in vaccinated and
unvaccinated girls and for the SCCS analysis. This cohort
consisted of girls born in 1993–1997 from GPs who agreed
to make data available for linkage with the vaccination
registry (n=20 GPs).
Case selection
Patients with newly diagnosed migraine were retrospectively
identified within the study population. Potential cases were
selected if the patient record contained the ICPC-code N89
(migraine) or ‘migrai*’ in the free text during the study period
(n=24,183). All potential cases were manually validated by
review of the anonymous medical record. Migraine was coded
according to the diagnoses of the GP as definite, unclear/
possible, menstruation related, medication-overuse headache
or no migraine (n=4535). The date of onset of migraine
symptoms was defined, or if this was unknown, the date of
first entry of migraine symptoms in the patient record was
used. Based on this, cases were classified as incident if the
onset of first migraine symptoms or first entry of migraine
symptoms was within the study period (n=5509 of which 448
are 12–16 years of age), or as prevalent if the patient was
diagnosed with migraine before the study period or first
symptoms of migraine started before the study period
(n=14,139). Prevalent cases were excluded from further
analysis. In addition, the occurrence of aura was coded as
definite, unclear/possible, typical aura without headache or
absent. Finally, two categories were classified, namely ‘certain
migraine’ and ‘uncertain migraine’ [7]. Certain migraine refers
to patients with definite migraine and menstruation-related
migraine (n=321 12- to 16-year olds). Uncertain migraine
comprised patients with unclear/possible migraine and typical
aura without headache (n=127 12- to 16-year olds). The
identification process of migraine cases is described in Fig. 1.
HPV vaccination exposure
In the Netherlands, all girls aged 13–16 years were invited for
HPV catch-up vaccination in 2009, and 12-year-old girls were
invited from 2010 onwards. HPV vaccination consists of three
successive doses of the bivalent HPV-16/18 vaccine
(Cervarix®). All three doses have equal content. Vaccination
rounds were organised in March/April, April/May and
September/October. However, some girls started later or
skipped rounds. Girls not fully vaccinated received another
opportunity to complete the series in the next year. All admin-
istered doses were registered in the national vaccine registry,
Praeventis. Praeventis covers the entire Dutch population in
the age groups eligible for vaccination and is updated
continuously, as described by Van Lier et al. [29].
Girls born between 1993 and 1997 who were part of the
IPCI study population and were patients of the 20 GPs who
gave permission for data linkage were linked to the national
vaccination registry to determine their HPV vaccination status
and the number and dates of vaccine administration (n=2363,
Fig. 1). Probabilistic techniques were used for the linkage,
because wewere not able to use a personal identifier. With this
technique, (parts of) personal identifiers, i.e. postal code, date
of birth, first name, surname and citizen service number, were
taken into account to assess the probability that two records
from both databases were from the same person. This linkage
technique was validated in an earlier study byKemmeren et al.
[16]. A trusted third party was used to exclude identifying
variables from the research database.
Analysis
To identify a possible association between HPV vaccina-
tion and incident migraine, we analysed the data in three
different ways. First, age- and gender-specific incidence
rates of migraine were obtained for the period before (pre
2008) and after (post 2009/2010) vaccination. Incidence
rate ratios (IRRs) with 95 % confidence intervals were
calculated to compare the postvaccination period with the
pre-vaccination period. Males are included as a control to
indicate trends over time that were independent of HPV
vaccination as they were not eligible for HPV vaccination.
Second, a cohort analysis was performed to compare
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monthly incidence rates of migraine between vaccinated
and unvaccinated girls. “Unvaccinated” person time com-
prised the time from entry in the study until the date of the
end of the study (see above), the date of occurrence of an
event or the date of administration of the first dose, which-
ever came first. “Vaccinated” person time included the time
between administration of the first dose and the date of the
end of the study or the date of occurrence of the event,
whichever came first (Fig. 2). If the date of the end of the
study was earlier than 31 December 2010, the patient was
censored. Time after the first dose was divided in months,
providing incidence in consecutive months after vaccina-
tion. IRRs of these periods compared to the reference peri-
od were estimated. Confidence intervals were estimated by
the mid-P exact method [20]. Third, SCCS analysis was
used to compare the incidence of migraine in the high-risk
and non-high-risk periods. Only HPV-vaccinated girls with
incident migraine were included in the analysis, whereby
each case acts as its own control. A primary high-risk
period of 6 weeks following each dose was defined, ac-
cording to other studies on neurological events following
immunisation [6, 10, 24]. Furthermore, three different high-
Fig. 1 Process of identification of migraine cases
Fig. 2 Calculation of the person time used in the cohort analysis
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risk periods were defined, one longer period of 13 weeks
and two shorter periods of 4 and 2 weeks, to conduct
sensitivity analyses. Additionally, we adjusted for school
holidays (between 1 July and 31 August and between 20
December and 7 January) because we observed a lower
incidence of migraine in those periods. This potentially
can cause bias because vaccination was given outside these
periods. Furthermore, no seasonality was observed in the
incidence of migraine.
Results
Pre- and postvaccination period incidences of migraine
The study period comprised a total of 73,245 person years for
12- to 16-year-old boys and girls, in which 321 certainmigraine
cases and 127 uncertain migraine cases occurred. In 12- to 16-
year-old girls, the incidence rate of migraine was slightly higher
in the postvaccination period (2009/2010) compared to the pre-
vaccination period (2008; Table 1). The IRR for certain mi-
graine was 1.14 (95 % CI 0.82–1.62), and the IRR for certain+
uncertain migraine was 1.10 (95 % CI 0.83–1.49). Moreover,
in 12- to 16-year-old males, the postvaccination incidence rate
of migraine was also slightly higher, but not significantly
different, than the pre-vaccination incidence rate (Table 1), with
an IRR of 1.21 (95 % CI 0.77–1.97) for certain migraine and
1.20 (95 % CI 0.83–1.78) for certain and uncertain migraine.
Cohort analysis
In the cohort analysis, we included 2005 girls eligible for HPV
vaccination in IPCI who could be linked to the vaccination
registry. Of these girls, 1306 (65.1 %) received at least one
dose of HPV vaccination, 1275 (63.3 %) received at least two
doses, and 1228 (61.3 %) received all three doses within the
study period. Adherence to the dosing schedule was good:
97 % received the second dose within 2 months after the first,
and 84 % of all vaccinated girls received the third dose within
7 months after the first. In 2009/2010, 22 girls had incident
migraine (14 certain and eight uncertain), of which 11
(50.0 %) were vaccinated for HPV and 11 (50.0 %) were
unvaccinated.
The IRRs for migraine in monthly periods following the
first dose compared to migraine in unvaccinated girls or
migraine occurring in the period before vaccination ranged
between 0.0 and 3.0 (month 6; Fig. 3). None of these IRRs
were statistically significant, and increases in IRRs were not
related to the months in which vaccination occurred. Figure 4
shows a lower cumulative proportion of migraine for HPV-
vaccinated girls than for unvaccinated girls; however, confi-
dence intervals were overlapping. Increases in the cumulative
proportion of migraine during or following vaccination were
observed in both vaccinated and unvaccinated girls.
Self-controlled case series (SCCS) analysis
The association between HPV vaccination and migraine was
tested using a hypothesis-testing SCCS study including 11
incident migraine cases in vaccinated girls. Of them, six were
certain migraine cases and five were uncertain cases. Ten out
of the 11 cases received three doses of HPV vaccine, and one
certain case received only one dose. Of the six certain mi-
graine cases, four occurred in 2009 and two occurred in 2010,
and of the five uncertain cases, two occurred in 2009 and three
occurred in 2010. The mean duration of observation in the
study period was 1.8 years (range 0.7–2.0).
Three events occurred in the high-risk period of 6 weeks
post HPV vaccination. The events were equally divided over
the three doses, and they took place on day 8, 37 and 23
following the first, second and third dose, respectively. We
found no statistically significant elevated risk of migraine in
the four defined high-risk periods versus non-high-risk pe-
riods; however, the risk estimates ranged between 2.1 and 6.3
(Table 2).
Table 1 Pre- and postvaccination
period incidences of incident mi-
graine for 12- to 16-year-old
females and males
Certain migraine (n=321) Certain+uncertain
migraine (n=448)
Females Incidence/100,000 person
years (95 % CI)
2008 (pre-vaccination period) 421 (303–569) 581 (442–752)
2009 (pre-vaccination period) 454 (360–566) 594 (485–721)
2010 (postvaccination period) 505 (408–618) 686 (572–817)
Males Incidence/100,000 person
years (95 % CI)
2008 (pre-vaccination period) 208 (130–314) 312 (215–438)
2009 (pre-vaccination period) 234 (170–314) 354 (274–450)
2010 (postvaccination period) 267 (201–349) 394 (312–491)
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Discussion
In this study, we studied the association between HPV vacci-
nation and migraine. A slightly, but not significantly, higher
incidence of migraine among 12- to 16-year-old girls was
found in the postvaccination years compared to the pre-
vaccination period. Furthermore, we found no significantly
higher risk of migraine in high-risk weeks (defined as primary
6 weeks, and secondary 13 weeks, 4 weeks and 2 weeks) after
each HPV dose compared to non-high-risk weeks. However,
risk point estimates ranged between 2.2 and 6.3 for certain
migraine and between 2.1 and 3.4 for certain and uncertain
migraine. Finally, no significantly higher risk of migraine was
found in the months following vaccination compared to un-
vaccinated girls.
The number of migraine reports following HPV vaccina-
tion in the Netherlands received through the passive safety
surveillance system was with eight cases following almost
800,000 doses higher than that in the UK. In the UK, during
the first 2 years following introduction of the bivalent HPV
vaccine, 17 reports of migraine out of at least 4.5 million doses
of HPV vaccine were received through the Yellow Card
Scheme [4]. A possible explanation for the difference in
reporting rate can be the difference in age groups targeted
Fig. 3 IRRs for incident migraine in monthly periods following the date
of first vaccination compared to migraine in unvaccinated girls. Notes: the
months following the three doses according to the vaccination schedule
are in red circles. The dashed line represents the cut-off value for an
association between HPV vaccination and migraine
Fig. 4 Cumulative proportion of
incident migraine with 95 %
confidence intervals in HPV-
vaccinated and unvaccinated girls
during the study period. Note: the
vertical dashed lines showed the
vaccination moments according
to the schedule
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for HPV vaccination, including the catch-up campaign. In the
Netherlands, girls 12 to 16 years of age were invited as in the
UK, girls aged 12 up to 18 years. Furthermore, possible
differences in spontaneous reporting between countries may
lead to different reporting rates. Finally, the adverse media
attention for the safety of the HPV vaccine in the Netherlands
could have played a role also. Nevertheless, we think it is
important to follow up a possible signal to maintain public
faith in the NIP as high as possible. To date, little is known
about the occurrence of migraine following HPV vaccination
despite the fact that headaches are one of the most reported
adverse events [9, 11, 19]. Unfortunately, trials in which
adverse events were studied did not specify the characteristics
of the headaches. However, the frequency of headaches in the
week before vaccination was found to be comparable or
higher than that in the week following HPV vaccination
[25]. Moreover, it is notable that the incidence of migraine
among girls rises during puberty. The addition of pubescent
girls in the NIP as a new target group for HPV vaccination
could have contributed to sudden reports of migraine through
the passive safety surveillance system.
The slightly higher, although not statistically significant,
incidence ofmigraine observed among 12- to 16-year-old girls
in the postvaccination years compared to the pre-vaccination
year, irrespective of vaccination status, was also found for
boys in the same age group. This might indicate that there
are other unknown causes for an increase in migraine inci-
dence during this period. No changes were made in headache
guidelines for GPs before or during the study period. A
possible explanation might be the earlier diagnosis of mi-
graine over the years: the incidence of migraine decreased in
30- to 45-year olds and increased in 10- to 29-year olds (data
not shown). However, an association is difficult to detect with
this method when the effect of HPV vaccination on the inci-
dence of migraine is small or present only for a small time
period after vaccination and because only approximately half
of the girls were vaccinated against HPV.
The cohort and self-controlled case series analysis also
showed no significantly increased risk of migraine in girls
who were vaccinated, although the estimated RRs ranged
from 2.1 to 6.3. Unfortunately, the number of cases included
in the analysis was small, and therefore, we had little power to
detect a potential association. The results may depend on the
definition of the risk periods, as we did not have an established
hazard function or biological mechanism for a potential asso-
ciation. Consistent with studies on other neurological events
(e.g. Guillain-Barré syndrome (GBS)) following
immunisation, we defined a primary high-risk period of
6 weeks following each dose [6, 10, 24]. In studies of more
insidious diseases, such as autoimmune and neurological dis-
eases, after quadrivalent HPV vaccination, longer risk win-
dows of 180 days were used [1, 5]. We conducted a sensitivity
analysis to explore the effect of a potential misclassification:
we defined three additional high-risk periods, one longer
period of 13 weeks and two shorter periods of 4 and 2 weeks.
More or less comparable risk estimates were found by using
these longer and shorter high-risk periods, which indicates
that the 6-week period may not have led to underestimation.
In addition to statistical analyses that may establish an
association, a declarative pathophysiological mechanism is
of importance prior to determining potential causality. Al-
though we did not find any plausible pathophysiological
mechanism that explains how migraine can be caused by
HPV vaccination, vaccination may possibly act as a trigger
for migraine. However, according to many experts, the value
of migraine triggers is overestimated [14], but often highly
valued by patients. In many patients, there is a genetic predis-
position for migraine, although this is difficult to prove in a
complex polygenic disease such as migraine. It is not known
why in some patients with a genetic predisposition to migraine
Table 2 Results of the self-
controlled case series (SCCS)
analysis for HPV-vaccinated girls
with incident migraine
a One following the first dose and
one following the second dose
bOne following the first dose, one
following the second dose and
one following the third dose
c Adjusted for school holidays
Certain migraine Certain+uncertain migraine
6 weeks high-risk period
Within high-risk period
Number of events 2a 3b
Number of days observed 506 984
Non-high-risk period
Number of events 4 8
Number of days observed 3389 6076
RR (95 % CI) univariate 4.3 (0.69–26.6) 2.9 (0.71–11.7)
RR (95 % CI) adjustedc 6.3 (0.80–49.1) 2.8 (0.66–12.0)
Sensitivity analysis Certain+uncertain migraine
RR (95 % CI) univariate
Certain migraine RR (95 % CI)
univariate
13 weeks high-risk period 4.6 (0.74–28.5) 3.4 (0.88–12.8)
4 weeks high-risk period 2.2 (0.24–20.3) 2.3 (0.48–11.4)
2 weeks high-risk period 4.5 (0.49–41.2) 2.1 (0.26–16.7)
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develop symptoms and some do not develop symptoms [22,
23]. However, the SCCS method adjusts for such time-
independent factors.
A limitation of the study is misclassification of the out-
come: underdiagnosis of migraine may have occurred because
we used an observational database fromGPs. Patients who did
not go to a GP do not appear in the database. Furthermore, we
defined the date of onset of migraine symptoms. However, if
this was unknown, the date of first entry of migraine symp-
toms in the patient record was used. This may have led to
some misclassification, as patients are only likely to consult
their GP if multiple headache attacks have occurred. This
misclassification could have led to overdiagnosis if the pre-
sumed date was within the high-risk period but the actual date
of symptom onset was before the vaccination. On the other
hand, misclassification of the onset date could have led to
underdiagnosis if the presumed date was classified after the
high-risk period but the actual date of onset of symptoms lies
within the high-risk period.
This study could also include selection bias. First, in this
study, a slightly higher percentage of girls was fully vaccinated
(61 %) compared to the national vaccination coverage (49–
56 %). Vaccinated persons are more likely to be indigenous
Dutch and live in areas with higher socioeconomic status [21].
Secondly, only data of a small number of GPs (n=20) was
available for linkage to the vaccination registry. Because avail-
ability was based on permission of the GP for data linkage, the
introduction of selection bias due to this was unlikely.
Finally, residual confounding may have occurred in the
SCCS analysis and in the cohort analysis because there was
no information available on other risk factors for migraine,
such as oestrogen level [13]; therefore, we were unable to
adjust for these other risk factors.
In conclusion, using different methods of analysis, no
statistically significant association between HPV vaccina-
tion and incident migraine was found. Because the number
of cases was limited, these results should be interpreted
with caution. Larger studies are warranted to investigate
this topic.
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